Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T19:49:23.361Z.
Calculation as of: 2026-10-06T19:49:23.361Z.
Quote observation: 2026-10-06T19:45:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79812cd6dc1246c3578cfde2233ee829467ffef9b0062efd9074e0cc555abd58
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$666.85M
EV/FCF Ratio
13.12x
TTM Avg
10.66x
3Y Avg
30.61x
5Y Avg
30.61x
Market Cap
$688.40M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | $672.56M | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $676.73M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.85M | 13.12x | 10.66x | 30.61x | 30.61x |
| Annexon, Inc. (ANNX)vs › | $660.42M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $685.41M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $686.47M | N/A | N/A | N/A | N/A |
| Faeth Therapeutics, Inc. (FTH)vs › | $697.19M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $660.17M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $688.40M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $658.68M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
